Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT04758975RecruitingPhase 2
Venetoclax plus rituximab plus ibrutinib for early CLL
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
Milan, MIAges 18–65 - NCT04763447RecruitingPhase 4
Short omalizumab treatment for severe allergic asthma
This trial tests whether stopping omalizumab for a short time (or using it differently) can be safe for adults with severe allergic asthma who are doing well. It may help some people avoid long-term injections, but only if asthma remains well controlled.
Paris, Île-de-France RegionAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chicago, IllinoisAges 13 years+ - NCT04771507RecruitingPhase 1/Phase 2
Testing intermittent ibrutinib for advanced chronic lymphocytic leukemia
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
TrondheimAges 18 years+ - NCT04775745RecruitingPhase 1
Oral drug test for relapsed or refractory B-cell blood cancers
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Durham, North CarolinaAges 18 years+ - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT04776395RecruitingPhase 2
Iberdomide to treat intermediate or high-risk smoldering myeloma
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT04783441Recruiting
Continuous glucose sensor study after kidney transplant
This study checks whether using a continuous glucose monitor (a sensor that tracks sugar throughout the day) is helpful and practical for people with a recent kidney transplant and type 2 diabetes on insulin. You may need to wear the sensor continuously and still do finger-stick glucose checks for safety.
Sacramento, CaliforniaAges 18 years+ - NCT04784364Recruiting
Study of immune treatments at Mount Sinai
This study follows people who are receiving immune-related medications (called biologics or immune modulators) at Mount Sinai. It aims to better understand how these treatments affect the immune system and health over time, which may help improve future care.
New York, New YorkAges 12 years+ - NCT04785989Recruiting
Blood and marrow testing to study metabolism in CLL
This study measures how your body’s metabolism works in people with chronic lymphocytic leukemia (CLL). It uses blood tests, and for some people, a bone marrow sample, to better understand what’s happening and potentially guide future treatments.
Madison, WisconsinAges 18 years+ - NCT04791891Recruiting
Study collecting information about low back pain
This study asks adults with low back pain to complete an online questionnaire so researchers can better understand how low back pain affects daily life. Your answers may help build a larger “core dataset” for future research.
Montreal, QuebecAges 18 years+ - NCT04792502RecruitingPhase 2
Mosunetuzumab plus lenalidomide for untreated follicular or marginal lymphoma
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
New Haven, ConnecticutAges 18 years+ - NCT04794296Recruiting
Care plan for children newly diagnosed with acute lymphoblastic leukemia
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
AbidjanAges Up to 18 years - NCT04795882RecruitingPhase 1
Study of modular CAR T therapy for multiple myeloma
This early-phase study tests a personalized type of immune therapy called modular CAR T for people with relapsed or treatment-resistant multiple myeloma. It aims to see whether the therapy can reduce the myeloma, including in cases where standard treatments have not worked.
London, County (Optional)Ages 18 years+ - NCT04796844Recruiting
Asthma real-world study for adults in other health studies
This study follows adults with asthma in real life to better understand asthma care and outcomes. You may be invited if you already joined another asthma-related or health-related observational study and don’t have certain major lung or health conditions.
GenovaAges 18–99 - NCT04797767RecruitingPhase 1/Phase 2
Venetoclax plus CLAG-M for high-risk AML
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Seattle, WashingtonAges 18 years+ - NCT04798651Recruiting
Study immune blood and spinal fluid cells in multiple sclerosis
This study looks at different immune cells in blood and, sometimes, spinal fluid (CSF) to understand what’s driving multiple sclerosis (MS) or early MS-like symptoms. Your participation may help researchers better explain the disease and potentially improve how it’s diagnosed or treated.
BordeauxAges 18 years+ - NCT04800458Recruiting
Testing antibody findings to confirm autoimmune low platelets
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
PessacAges 18 years+ - NCT04804553RecruitingPhase 3
Apremilast for children with active juvenile psoriatic arthritis
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
BregenzAges 5–17 - NCT04806620Recruiting
Online app study for brain inflammation lifestyle data
This study uses a digital platform (app/website) to collect lifestyle and symptom information to better understand brain inflammation. You may qualify if you have certain conditions like Long COVID, migraines, autoimmune disease, inflammatory gut issues, mood disorders, or if you are a healthy comparison person.
Delafield, WisconsinAges 2 years+ - NCT04806568Recruiting
Cognitive training to help brain flexibility in multiple sclerosis
This study tests whether structured cognitive exercises can improve “neuroplasticity,” meaning how flexible and changeable the brain is. It includes people with multiple sclerosis and healthy volunteers, and uses tasks plus brain scans to see what changes over time.
Thessaloniki, Central MacedoniaAges 18–65 - NCT04807881RecruitingPhase 1
Study of keynatinib for certain hard-to-treat lymphomas
This Phase 1 trial tests keynatinib, a new medicine, in people with specific types of lymphoma that have returned or not responded to earlier treatment. It aims to find a safe dose and see whether it can shrink tumors in the brain or elsewhere in the body, depending on the group.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04815356RecruitingPhase 1
T cells designed to attack a blood cancer called hairy cell leukemia
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
Bethesda, MarylandAges 18 years+ - NCT04815668Recruiting
Acupuncture for moderate-to-severe seasonal allergy rhinitis
This trial tests whether acupuncture at a specific spot behind the nose can reduce symptoms from seasonal allergies (triggered by things like grass or birch pollen). It may help if your allergy symptoms are moderate to severe and have lasted for a long time.
BeijingAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.